Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.

Area of Science:

• Oncology
• Immunology
• Genitourinary Malignancies

Background:

• Immunotherapy is the 5th pillar of cancer care, revolutionizing treatment for genitourinary malignancies.
• Immune checkpoint inhibitors (ICIs) show survival benefits in renal cell carcinoma, urothelial carcinoma, and prostate cancer.

Purpose of the Study:

• To explore the challenges and future directions of immunotherapy in genitourinary cancers.
• To address the need for identifying patient responders and overcoming resistance to ICIs.

Main Methods:

• Review of current immunotherapy applications and challenges.
• Exploration of combination and sequencing strategies with ICIs.
• Discussion of unmet needs in advanced genitourinary malignancies.

Main Results:

• ICIs offer meaningful survival benefits and durable responses in select genitourinary cancer patients.
• Biomarker development remains complex, limiting benefits to a minority of patients.
• Combination and sequencing strategies are under active investigation.

Conclusions:

• Further research is crucial to identify optimal patient selection for ICIs.
• Novel therapeutic strategies are needed to overcome resistance and improve quality of life.
• Validating efficacy in real-world settings is essential for advancing cancer care.